Psyence BioMed Doses Multiple Patients in Adjustment Disorder Study

Patients Dosed With Psilocybin in Phase 2b Trial for Adjustment Disorder in Palliative Care

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

Psyence BioMed doses multiple patients in adjustment disorder study

Psyence Biomedical (Psyence BioMed) has dosed multiple participants in its ongoing Phase IIb clinical study assessing nature-derived psilocybin alongside psychotherapy as a potential therapy for adjustment disorder in palliative care.The post Psyence BioMed doses multiple patients in adjustment disorder study appeared first on Clinical Trials Arena.